Healthcare Professionals

eThalED Webinar Series: Current Standard Care & New Advances in Iron Chelation
eThalED Webinars

eThalED Webinar Series: Current Standard Care & New Advances in Iron Chelation

TIF´s last webinar for the eThalED series for Medical Specialists on October 16, 2020, featured Dr Farrukh Shah, Consultant Haematologist, Whittington Hospital, London, UK, who reviewed all the current practices…
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Clinical News

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
Νέα

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”
Νέα

Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
eThalED Webinar Series: Iron Monitoring in Thalassaemia
Webinars

eThalED Webinar Series: Iron Monitoring in Thalassaemia

TIF´s 5th consecutive webinar for Medical Specialists and Healthcare Professionals was conducted on 7 September 2020 and revolved around the topic of ”Iron Monitoring in Thalassaemia”. Dr Paul Telfer, Consultant…
eThalED Webinar Series: Blood Transfusion in Thalassaemia
Webinars

eThalED Webinar Series: Blood Transfusion in Thalassaemia

TIF´s 4th Webinar for Medical Specialists and Healthcare Professionals, organised as part of our eThalED Course, was successfully held on Monday, 31 August 2020. Prof. Constantina Politis, Associate Professor of…
IMPORTANT ANNOUNCEMENT: TIF’s Renzo Galanello Fellowship Programme 2020 To Be Rescheduled and Compressed
Νέα

IMPORTANT ANNOUNCEMENT: TIF’s Renzo Galanello Fellowship Programme 2020 To Be Rescheduled and Compressed

Due to some difficulties and restrictions encountered as a result of the COVID-19 pandemic, the Renzo Galanello Fellowship Programme 2020 will not be offered in its full length and as initially…
Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial
Clinical News

Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial

One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical…
Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early
Member News

Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early

Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…
The eThalED Course Webinar Series Return With a New Session on Iron Monitoring in Thalassaemia
Νέα

The eThalED Course Webinar Series Return With a New Session on Iron Monitoring in Thalassaemia

TIF´s upcoming webinar on ”Iron Monitoring in Thalassaemia”, specially designed and launched for medical specialists and healthcare professionals with a particular interest in the field of haemoglobin disorders and thalassaemia,…
Back to top button